ReviewCirculation. Heart failure2019
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Review in Circulation. Heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 271 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening for Cardiac Amyloidosis With Nuclear Cardiology for Minority Populations
A National Survey of Prevalence and Accuracy of Echocardiographic Red Flags of Amyloid Cardiomyopathy in Consecutive Patients Undergoing Routine Echocardiography.
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
Phenotypic Manifestations of Hereditary ATTR Amyloidosis Val50Met Variant in a Non-endemic Area. Descriptive Study
Who cites it
271 citing papers in PubMed, 7 syntheses or guidelines pooled it, 522 citations in OpenAlex.
- A systematic review for the evidence of recommendations and guidelines in hybrid nuclear cardiovascular imaging.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Archivos de cardiologia de Mexico · 2024Guideline
- Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Pooled it
- Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review.BMC musculoskeletal disorders · 2023Pooled it
- Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.ESC heart failure · 2022Pooled it
- Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.European journal of clinical investigation · 2021Pooled it
- Performance of bone tracer for diagnosis and differentiation of transthyretin cardiac amyloidosis: a systematic review and meta-analysis.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Pooled it
- Amyloid Transthyretin Cardiomyopathy in Elderly Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.Journal of the American Heart Association · 2023Trial
- Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.European heart journal. Quality of care & clinical outcomes · 2022Trial
- Multimodal artificial intelligence to predict cardiomyopathy development in hereditary transthyretin amyloidosis.Open heart · 2026Article
- CRISPRing through time: How cutting-edge technology is revolutionizing life sciences and medicine.Molecular therapy. Nucleic acids · 2026Review
- Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.European heart journal · 2026Article
- Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B.JACC. Asia · 2026Article
- Subtype specific artificial intelligence modelling of cardiac amyloidosis using echocardiography and electrocardiography.European heart journal. Digital health · 2026Article
- Cardiac magnetic resonance T1 mapping for amyloid cardiomyopathy in patients with heart failure.European heart journal. Imaging methods and practice · 2026Article
- Patient Characteristics and Diagnosis of Transthyretin Amyloid Cardiomyopathy in Japan: Baseline Analysis of J-COSSA.JACC. Asia · 2026Article
- Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States.Journal of the American Heart Association · 2026Article
- Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.Heart failure reviews · 2026Review
- Expert Consensus and Clinical Pathway Recommendations for Transthyretin Amyloid Cardiomyopathy in Malaysia.International journal of heart failure · 2026Review
- Indication and electrical performance of conventional, resynchronization, and conduction system pacing in transthyretin amyloid cardiomyopathy.Heart rhythm O2 · 2026Article
211 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 5 countries.
Funding
Abstract
Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils that deposit in various tissues and organs. ATTR amyloidosis is debilitating and associated with poor life expectancy, especially in those with cardiac dysfunction, but a variety of treatment options have recently become available. Considered a rare disease, ATTR amyloidosis may be more prevalent than thought, particularly in older persons. Diagnosis is often delayed because of a lack of disease awareness and the heterogeneity of symptoms at presentation. Given the recent availability of effective treatments, early recognition and diagnosis are especially critical because treatment is likely more effective earlier in the disease course. The Amyloidosis Research Consortium recently convened a group of experts in ATTR amyloidosis who, through an iterative process, agreed on best practices for suspicion, diagnosis, and characterization of disease. This review describes these consensus recommendations for ATTR associated with cardiomyopathy as a resource to aid cardiologists and others in the recognition and diagnosis of ATTR associated with cardiomyopathy. Included in this review is an overview of red flag signs and symptoms and a recommended diagnostic approach, including testing for monoclonal protein, scintigraphy, or biopsy and, if ATTR associated with cardiomyopathy is identified, TTR genotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.